Trial Profile
Phase II Study of Erlotinib, An Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor, in the Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Skin
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Skin cancer; Squamous cell cancer
- Focus Therapeutic Use
- 08 May 2019 Status changed from active, no longer recruiting to completed.
- 12 Apr 2019 Planned End Date changed from 31 Mar 2019 to 31 May 2019.
- 12 Apr 2019 Planned primary completion date changed from 31 Mar 2019 to 31 May 2019.